
  
    
      
        
        It_PRP does_VBZ n't_RB take_VB a_DT trained_VBN physician_NN to_TO know_VB that_IN a_DT disease_NN needs_VBZ to_TO be_VB diagnosed_VBN to_TO be_VB
        treated_VBN ._. And_CC it_PRP does_VBZ n't_RB take_VB an_DT economist_NN to_TO know_VB that_IN a_DT disease_NN cannot_NN be_VB diagnosed_VBN if_IN the_DT
        required_JJ tools_NNS are_VBP unaffordable_JJ or_CC impractical_JJ ._. The_DT absence_NN of_IN early_JJ diagnosis_NN and_CC
        treatment_NN is_VBZ particularly_RB problematic_JJ for_IN infectious_JJ disease_NN ,_, where_WRB the_DT lack_NN of_IN early_JJ
        treatment_NN or_CC isolation_NN can_MD result_VB in_IN an_DT epidemic_NN ._.
        Given_VBN the_DT technological_JJ requirements_NNS ,_, diagnosis_NN and_CC monitoring_NN of_IN HIV_NNP infection_NN is_VBZ
        problematic_JJ in_IN resource-poor_JJ areas_NNS ._. The_DT advent_NN of_IN rapid_JJ tests_NNS for_IN diagnosing_VBG HIV_NNP infection_NN
        represents_VBZ one_CD part_NN of_IN the_DT solution_NN ._. Less_RBR clear_JJ is_VBZ how_WRB patients_NNS diagnosed_VBN with_IN HIV_NNP
        infection_NN will_MD be_VB monitored_VBN ,_, given_VBN the_DT importance_NN of_IN CD_NNP 4_CD cell_NN counts_NNS ._. A_DT decrease_NN in_IN CD_NNP 4_CD
        +_NN T_NN lymphocytes—a_NN critical_JJ immune_JJ cell_NN infected_VBN by_IN HIV—is_NNP one_CD of_IN the_DT
        hallmarks_NNS of_IN HIV_NNP disease_NN ,_, and_CC CD_NNP 4_CD
        +_NN cell_NN number_NN is_VBZ a_DT key_JJ factor_NN in_IN determining_VBG disease_NN progression_NN and_CC
        monitoring_VBG treatment_NN ._. The_DT methods_NNS for_IN determining_VBG CD_NNP 4_CD
        +_NN cell_NN numbers_NNS are_VBP technically_RB complex_JJ ,_, expensive_JJ ,_, and_CC not_RB easily_RB
        transportable_JJ ._. These_DT factors_NNS severely_RB limit_VBP the_DT ability_NN to_TO monitor_VB HIV_NNP disease_NN in_IN locations_NNS
        where_WRB resources_NNS ,_, training_NN ,_, and_CC mobility_NN are_VBP limited_JJ ._.
        Lymphocytes_NNP are_VBP characterized_VBN by_IN cell_NN surface_NN markers_NNS ;_: thus_RB ,_, CD_NNP 4_CD
        +_NN lymphocytes_NNS express_VBP the_DT CD_NNP 4_CD marker_NN on_IN their_PRP$ surface_NN ._. Antibody_NNP probes_NNS
        that_WDT specifically_RB recognize_VB this_DT and_CC other_JJ cell_NN surface_NN markers_NNS (_( such_JJ as_IN CD_NNP 8_CD ,_, which_WDT
        distinguishes_NNS that_WDT lymphocyte_NN population_NN from_IN CD_NNP 4_CD
        +_NN lymphocytes_NNS ,_, and_CC CD_NNP 3_CD ,_, which_WDT is_VBZ a_DT marker_NN for_IN all_DT T_NN lymphocytes_NNS )_) are_VBP
        used_VBN to_TO count_VB and_CC differentiate_VB various_JJ cell_NN populations_NNS ._. By_IN labeling_VBG cells_NNS with_IN
        fluorescently_RB tagged_VBN antibodies_NNS that_WDT recognize_VBP one_CD or_CC more_JJR cell_NN surface_NN molecules_NNS ,_, the_DT
        relative_JJ and_CC absolute_JJ numbers_NNS of_IN specific_JJ cells_NNS can_MD be_VB determined_VBN by_IN a_DT technique_NN called_VBD
        flow_NN cytometry_NN ._. The_DT labeled_VBN cells_NNS are_VBP passed_VBN through_IN the_DT flow_NN cytometer_NN ,_, where_WRB the_DT
        fluorescent_NN probes_NNS are_VBP activated_VBN by_IN lasers_NNS in_IN a_DT manner_NN that_WDT can_MD be_VB read_VBN by_IN specific_JJ
        detectors_NNS ._. The_DT CD_NNP 4_CD
        +_NN cell_NN number_NN is_VBZ directly_RB correlated_JJ with_IN the_DT resultant_JJ fluorescent_NN
        intensity_NN and_CC other_JJ light_JJ scatter_NN properties_NNS ._. The_DT problem_NN is_VBZ that_DT flow_NN cytometry_NN requires_VBZ
        costly_JJ reagents_NNS and_CC substantial_JJ technical_JJ expertise—factors_NNS that_WDT limit_NN its_PRP$ use_NN in_IN less_JJR
        developed_JJ areas_NNS ._.
        Taking_VBG advantage_NN of_IN advances_NNS in_IN microfluidics_NNS ,_, digital_JJ imaging_NN ,_, and_CC cell_NN analysis_NN ,_,
        William_NNP Rodriguez_NNP and_CC colleagues_NNS now_RB report_VBP on_IN a_DT way_NN to_TO count_VB CD_NNP 4_CD
        +_NN cells_NNS in_IN a_DT relatively_RB quick_JJ ,_, easy_JJ ,_, and_CC affordable_JJ manner_NN ._. Small_JJ
        volumes_NNS of_IN blood_NN (_( an_DT amount_NN that_WDT could_MD be_VB obtained_VBN by_IN a_DT finger_NN prick_NN as_IN opposed_VBN to_TO drawing_VBG
        blood_NN from_IN a_DT vein_NN )_) are_VBP labeled_VBN as_IN in_IN flow_NN cytometry_NN ,_, but_CC with_IN far_RB less_JJR of_IN the_DT expensive_JJ
        reagents_NNS ._. Microfiltration_NNP allows_VBZ the_DT labeled_VBN CD_NNP 4_CD
        +_NN cells_NNS to_TO be_VB captured_VBN and_CC separated_JJ from_IN red_JJ blood_NN cells_NNS ,_, another_DT
        simplification_NN relative_JJ to_TO flow_VB cytometry_NN ._. Digital_NN images_NNS of_IN the_DT labeled_VBN cells_NNS ,_, obtained_VBN by_IN
        digital_JJ fluorescence_NN microscopy_NN ,_, are_VBP then_RB analyzed_VBN by_IN newly_RB developed_VBN software_NN that_WDT can_MD
        distinguish_VB the_DT CD_NNP 4_CD ,_, CD_NNP 8_CD ,_, and_CC CD_NNP 3_CD labels_NNS ,_, thus_RB allowing_VBG determination_NN of_IN absolute_JJ CD_NNP 4_CD
        +_NN counts_VBZ ,_, CD_NNP 4_CD
        +_NN percentages_NNS ,_, and_CC CD_NNP 4_CD
        +_NN :_: CD_NNP 8_CD
        +_NN lymphocyte_NN ratios_NNS ._.
        Rodriguez_NNP et_CC al_NN ._. found_VBD that_IN this_DT new_JJ method_NN was_VBD less_RBR accurate_JJ than_IN flow_NN cytometry_NN for_IN
        determining_VBG absolute_JJ CD_NNP 4_CD
        +_NN lymphocyte_NN counts_VBZ above_IN 500_CD cells_NNS /_NN mm_NN 3_CD (_( levels_NNS that_WDT are_VBP typically_RB not_RB
        relevant_JJ for_IN monitoring_VBG HIV-infected_NNP individuals_NNS )_) ._. But_CC the_DT method_NN was_VBD as_RB accurate_JJ as_IN flow_NN
        cytometry_NN at_IN clinically_RB relevant_JJ levels_NNS of_IN CD_NNP 4_CD +_NN cells_NNS for_IN HIV-infected_NNP adult_NN individuals_NNS ._.
        Although_IN only_RB a_DT small_JJ number_NN of_IN pediatric_JJ patients_NNS were_VBD examined_VBN (_( and_CC thus_RB statistical_JJ
        significance_NN could_MD not_RB be_VB ascertained_JJ )_) ,_, the_DT method_NN appears_VBZ to_TO be_VB also_RB effective_JJ in_IN
        determining_VBG CD_NNP 4_CD
        +_NN lymphocyte_NN percentages_NNS in_IN children_NNS ._.
        The_DT detection_NN system_NN used_VBN in_IN the_DT present_JJ report_NN is_VBZ a_DT tabletop_NN instrument_NN that_WDT serves_VBZ as_IN
        a_DT prototype_NN for_IN a_DT fully_RB portable_JJ handheld_JJ model_NN ,_, which_WDT is_VBZ now_RB under_IN development_NN ._. After_IN some_DT
        modest_JJ training_NN ,_, such_JJ a_DT tool_NN should_MD allow_VB a_DT variety_NN of_IN health-care_NN workers_NNS in_IN remote_JJ areas_NNS
        to_TO accurately_RB analyze_VB the_DT CD_NNP 4_CD
        +_NN status_NN of_IN HIV-infected_NNP patients_NNS (_( the_DT basis_NN for_IN treatment_NN decisions_NNS )_)
        locally_RB ._. In_IN an_DT accompanying_VBG Perspective_NNP discussing_VBG this_DT new_JJ tool_NN (_( DOI_NNP :_:
        10_CD ._. 1371_CD /_NN journal_NN ._. pmed_JJ ._. 0020214_CD )_) ,_, Zvi_NNP Bentwich_NNP argues_VBZ that_IN before_IN it_PRP is_VBZ ready_JJ for_IN widespread_JJ
        use_NN ,_, several_JJ issues_NNS still_RB need_VBP to_TO be_VB resolved_VBN ,_, such_JJ as_IN its_PRP$ final_JJ cost_NN and_CC its_PRP$ applicability_NN
        to_TO pediatric_JJ patients_NNS ._. “ Despite_IN these_DT reservations_NNS ,_,” he_PRP says_VBZ ,_, “ the_DT authors_NNS of_IN this_DT study_NN
        should_MD be_VB commended_JJ for_IN addressing_VBG an_DT extremely_RB important_JJ issue_NN and_CC developing_VBG this_DT novel_NN
        approach_NN for_IN counting_VBG CD_NNP 4_CD in_IN patients_NNS with_IN HIV_NNP ._.”
      
    
  
